Browse the corpus

Antiepileptic drug-level monitoring has been integral to seizure management since the introduction of antiseizure medications. The challenge lies in maintaining drug levels within therapeutic margins despite numerous factors influencing serum concentrations. Pharmacokinetic factors, including absorption, distribution, metabolism, and excretion, significantly affect drug levels. Diet, other drugs, and nutritional status can alter these processes. Drug metabolism through systems like cytochrome P450 and conjugation reactions plays a vital role, especially when multiple drugs are administered concurrently. Clinical evaluation, supported by electroencephalograms and magnetic resonance imaging, forms the basis for diagnosing epilepsy, with drug levels serving as an adjunct for assessing efficacy in specific situations. The International League Against Epilepsy (ILAE) provides guidelines on best practices for therapeutic drug monitoring, highlighting scenarios where this approach is particularly advantageous. This activity emphasizes the importance of understanding these guidelines and recent studies regarding interpreting drug levels, considering individual patient factors and treatment goals. Effective communication about treatment plans and the reasons for drug monitoring are crucial. This activity examines the utility, diversity, and applicability of monitoring antiepileptic drug levels in various clinical contexts. Objectives: Identify common misconceptions associated with the practice of maintaining antiepileptic drug levels within laboratory-defined therapeutic ranges. Assess the efficacy, variability, and utility of monitoring antiepileptic drug levels in various settings. Implement appropriate practices to assess antiepileptic drug efficacy clinically. Implement effective collaboration and communication among interprofessional team members to improve outcomes for patients who might benefit from antiepileptic drug monitoring. Access free multiple choice questions on this topic.

Antiepileptic drug-level monitoring has been a common clinical practice since medications as treatment for epilepsy or seizures became available to the public.[1] The clinical efficacy in suppressing seizures can be difficult to predict for a prescribed dose of antiseizure medication. The purpose of pharmacokinetic and efficacy studies involving a large group of individuals is to establish the reference ranges for individual drugs. Maintaining antiepileptic drug levels within laboratory-defined therapeutic ranges can be difficult, and this is further compounded by the need to interpret the values given the context of patient factors and the pharmacokinetic factors unique in each clinical setting. Patients with epilepsy are primarily assessed through clinical evaluation and complementary investigation methods, such as electroencephalograms and magnetic resonance imaging.[2] The assessment of antiepileptic drug efficacy should also be clinical, and routine antiepileptic drug level monitoring should be utilized as a complementary tool in selected appropriate situations. A position paper on the best practice guideline has been published by the ILAE, which suggests specific situations where therapeutic drug level monitoring is most beneficial.[3] A patient's serum drug levels are affected by various pharmacokinetic factors, which may be grouped based on associated processes like absorption, bioavailability, distribution, metabolism, and excretion. These levels can vary between individuals receiving the same dose. They can be affected by dietary factors, volume of distribution, intercurrent drugs, and nutritional states affecting protein binding and drug metabolism. After absorption, the concentration of the drug in the plasma increases with the absorption rate. However, a balance between absorption and excretion rates inevitably occurs after the drug excretion begins. As the balance between these processes typically occurs at high absorption rates, calculating the bioavailability of a drug based on the individual's peak drug level can be erroneous. Some drugs are primarily excreted in their free form through the kidneys (eg, gabapentin), but most are excreted as metabolites. For example, monitoring drug levels in patients receiving oxcarbazepine is done by measuring its metabolite 10-monohydroxycarbamazepine.[4][5]

A patient's serum drug levels are affected by various pharmacokinetic factors, which may be grouped based on associated processes like absorption, bioavailability, distribution, metabolism, and excretion. These levels can vary between individuals receiving the same dose. They can be affected by dietary factors, volume of distribution, intercurrent drugs, and nutritional states affecting protein binding and drug metabolism. After absorption, the concentration of the drug in the plasma increases with the absorption rate. However, a balance between absorption and excretion rates inevitably occurs after the drug excretion begins. As the balance between these processes typically occurs at high absorption rates, calculating the bioavailability of a drug based on the individual's peak drug level can be erroneous. Some drugs are primarily excreted in their free form through the kidneys (eg, gabapentin), but most are excreted as metabolites. For example, monitoring drug levels in patients receiving oxcarbazepine is done by measuring its metabolite 10-monohydroxycarbamazepine.[4][5] Drug metabolism occurs through various processes, mostly phase I reactions: oxidation, reduction, and hydrolysis. One example is the cytochrome P450 system in the liver. Other processes fall under phase II reactions, which involve conjugation with an endogenous substance (eg, glucuronidation). Considering these processes is crucial when multiple medications with a common metabolism pathway are prescribed to the same individual.

Nurse practitioners, internists, primary care providers, neurologists, and emergency medicine physicians frequently encounter patients undergoing treatment with antiepileptic drugs. In the past, it was widely believed that routine drug monitoring of antiepileptics was beneficial, but this practice is no longer recommended, with a few exceptions. Instead, effective clinical monitoring relies on a supportive, patient-centered, interprofessional team treatment plan based on a therapeutic clinician-patient relationship with the support of nurses and pharmacists. A systematic review emphasizes that not every antiepileptic drug requires therapeutic drug monitoring. Therapeutic drug monitoring can enhance clinical care, particularly for antiepileptic medications with complex pharmacokinetics (eg, phenytoin), but its requirement differs based on the drug and individual patient factors.[36] This interprofessional team includes physicians, neurologists, nurse practitioners, physician assistants, nurses, and pharmacists. In addition to verifying appropriate dosing and performing medication reconciliation, pharmacists should emphasize the importance of medication compliance to patients and the need for close follow-up. Pharmacists should discuss the situation with clinicians managing the case if they have reason to suspect the patient is not adherent. Pharmacists and nurses should assist in educating patients about the adverse effects of the drugs so that they know when to report back to clinicians; they must also be alert to signs of therapeutic failure, which must be documented and reported to other team members as necessary so that regimen modification can be implemented if required. Only through an interprofessional team approach with open communication channels between all team members can the morbidity associated with anticonvulsant therapy be reduced and safe outcomes be achieved.

Nurses responsible for administering antiepileptic drugs should independently verify the dose and route of administration. They should also understand the potential adverse effects of the drugs and educate patients to enhance safety measures. If a dose does not appear appropriate, the nurse should contact the prescribing clinician immediately.

Several anticonvulsants have the potential to cause adverse cardiac effects when administered intravenously.[37] Thus, patients should be placed on a cardiac monitor, and their vital signs should be measured frequently. Any adverse effects should be immediately reported to the prescriber.